false 0001402328 0001402328 2024-12-10 2024-12-10 0001402328 us-gaap:CommonStockMember 2024-12-10 2024-12-10 0001402328 SBFM:CommonStockPurchaseWarrantsMember 2024-12-10 2024-12-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 10, 2024

 

SUNSHINE BIOPHARMA INC.

(Exact name of registrant as specified in its charter)

 

Colorado 001-41282 20-5566275

(State or other jurisdiction

of incorporation)

 (Commission File Number) (IRS Employer ID No.)

 

333 Las Olas Way,

CU4 Suite 433

Fort Lauderdale, FL 33301

(Address of principal executive offices) (zip code)

 

(954) 515-0810

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class Trading Symbol Name of Each Exchange on Which Registered
     
Common Stock, par value $0.001 SBFM The Nasdaq Stock Market LLC
Common Stock Purchase Warrants SBFMW The Nasdaq Stock Market LLC

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

   

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On December 10, 2024, Sunshine Biopharma Inc. (the “Company”) held its annual meeting of stockholders. At the meeting, (i) Dr. Steve N. Slilaty, Dr. Abderrazzak Merzouki, Dr. Rabi Kiderchah, Mr. David Natan, and Dr. Andrew Keller were each elected as directors of the Company to serve until the next annual meeting of stockholders or until their successors have been elected and qualified, and (ii) stockholders ratified the board of directors’ appointment of Bush & Associates CPA LLC as the Company’s independent registered public accounting firm for 2024.

 

The vote on these matters was as follows:

 

1. Election of Directors:   
  

 

FOR

 

 

WITHHELD

  BROKER NON-VOTE
Dr. Steve N. Slilaty  130,067,932  48,554  0
Dr. Abderrazzak Merzouki  130,080,510  35,976  0
Dr. Rabi Kiderchah  130,076,086  40,400  0
Mr. David Natan  130,070,417  46,069  0
Dr. Andrew Keller  130,075,596  40,890  0

 

2.  Ratification of the board of directors’ appointment of Bush & Associates CPA LLC as the Company’s independent registered public accounting firm for 2024.

 

FOR  AGAINST  ABSTAIN
130,089,305  15,456  11,725

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: December 10, 2024 SUNSHINE BIOPHARMA INC.
   
   
  By: /s/ Dr. Steve N. Slilaty                                           
  Dr. Steve N. Slilaty, Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 
v3.24.3
Cover
Dec. 10, 2024
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 10, 2024
Entity File Number 001-41282
Entity Registrant Name SUNSHINE BIOPHARMA INC.
Entity Central Index Key 0001402328
Entity Tax Identification Number 20-5566275
Entity Incorporation, State or Country Code CO
Entity Address, Address Line One 333 Las Olas Way,
Entity Address, Address Line Two CU4 Suite 433
Entity Address, City or Town Fort Lauderdale
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33301
City Area Code (954)
Local Phone Number 515-0810
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Title of 12(b) Security Common Stock, par value $0.001
Trading Symbol SBFM
Security Exchange Name NASDAQ
Common Stock Purchase Warrants [Member]  
Title of 12(b) Security Common Stock Purchase Warrants
Trading Symbol SBFMW
Security Exchange Name NASDAQ
Sunshine Biopharma (NASDAQ:SBFMW)
Historical Stock Chart
Von Nov 2024 bis Dez 2024 Click Here for more Sunshine Biopharma Charts.
Sunshine Biopharma (NASDAQ:SBFMW)
Historical Stock Chart
Von Dez 2023 bis Dez 2024 Click Here for more Sunshine Biopharma Charts.